ORTEXORTEX News
Live short interest, options flow, and signals — free on ORTEX.Sign up free →
Market Commentary

Bears Pile Into Wolfspeed and AI Chip Plays

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 1 min read

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

Short sellers have been busy this week. The data shows several notable moves across sectors, with one semiconductor name standing out above the rest.

WOLF remains the most shorted mid-cap on US exchanges. Its short interest hit 88.6% of free float as of 29 October. That is up 4.8 percentage points in just seven days. The cost to borrow sits near zero, making it cheap to maintain bearish bets. Bears see no sign of backing off.

CBRS also caught attention. Cerebras Systems saw its SI % FF climb from 14.9% to 20.1% in a week. The AI chip startup has been a social media talking point since its IPO. Short sellers are taking the other side of the hype.

Among the biggest one-week jumps, SRZN surged to 35.3% from 24.0%. LQDA moved to 26.6% from 18.6%. Both are small biotech names with binary catalysts ahead.

In a separate development, ORTEX data flagged a 424% weekly spike in short interest on the Grayscale Ethereum Staking Mini ETF. Shorts on crypto products are growing fast.

HTZ carries a 40% cost to borrow and 73.5% SI % FF. EVCM has the highest short score in the database at 97, with shares hard to borrow at 87.6% APR and availability near zero.

Retail attention on ETFs spiked this week too. Wikipedia data showed the T. Rowe Price Small-Mid Cap ETF and Neuberger Berman Short Duration Income ETF both hit 10 standard deviations above their own history in the week of 21 October.

Stocks in this article

How this article was generated

Generated
30 Oct 2026, 16:01
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationAlt DataIndex Rebalance

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.